Osteogenesis Imperfecta - Healing Genes

Osteogenesis Imperfecta

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

Multicenter Study to Evaluate Safety of Fresolimumab in Adults With Moderate-to-severe Osteogenesis Imperfecta

Phase 1


Researchers in OR and TX seek participants for a trial of an investigatory drug, Fresolimumab, for Osteogenesis Imperfecta. TGF-β is a protein important in bone formation. Studies have shown that increased TGF-β activity leads to lower bone mass and strength and increased fractures. Fresolimumab is an antibody that can silence TGF-β. This study seeks to explore the best dosage for the antibody: once, twice per year, or four times per year.

The study will require only visits for the injection of the drug and physical and lab assessments, for the frequency assigned over 12-month period.


  • Be 18 years of age or older
  • Have confirmed diagnosis of moderate-to-severe OI
  • Meet genetic screening requirements


  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Antibody infusion at each study visit, along with physical and lab assessments.
  3. Visits will be required a maximum of 4 times in a 12 month period.


The study sites are at Oregon Health Science University in Portland, OR (Map), and Baylor College of Medicine in Houston, TX (Map).

Contact: Dianne Dang  |  713-798-6694  |  [email protected]



Baylor College of Medicine

Genzyme, a Sanofi Company

Shriners Hospitals for Children

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Hospital for Special Surgery, New York

University of California, Los Angeles

University of Nebraska

Oregon Health and Science University

University of South Florida


Or go online:



Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader